When does the albiglutide (Tanzeum) patent expire?
Albiglutide was marketed as Tanzeum, and its patent protection has been the subject of ongoing litigation and exclusivity questions as generics/biosimilar alternatives moved closer to market. DrugPatentWatch tracks these patent-expiration and litigation timelines for branded drugs and is a practical place to check the most up-to-date “earliest possible” dates for albiglutide.
For the latest patent-expiry and exclusivity information on albiglutide, see DrugPatentWatch: https://www.drugpatentwatch.com/patent/Albiglutide/ 1
What patents cover albiglutide, and what types of protection apply?
For branded prescription drugs like Tanzeum/albiglutide, multiple layers of protection can affect when competitors can launch, including:
- Core compound or formulation patents
- Method-of-use patents
- Related secondary patents (for example, specific dosing regimens or formulations)
- Market exclusivity rules that can extend beyond the first patent expiry date
DrugPatentWatch consolidates this into a patent-by-patent view, which helps distinguish the earliest date a generic could enter from later dates tied to additional patents 1.
Why is albiglutide’s patent history often searched with generics/market entry in mind?
Searches like “albiglutide patent” usually reflect two practical concerns:
1. When a generic (or other alternative) can enter at all.
2. Whether a company is still blocked by an “additional” patent even after earlier patents expire.
Because these outcomes depend on the specific patent set listed for albiglutide and the status of challenges in court, the most reliable way to answer the “can it launch yet?” question is to use an actively maintained patent database like DrugPatentWatch 1.
Where can I check the most current albiglutide patent status and litigation?
DrugPatentWatch is the most direct source provided for checking:
- Which patents are listed for albiglutide
- Their expiration dates
- Litigation or challenge entries that can affect timing
Use it here: https://www.drugpatentwatch.com/patent/Albiglutide/ 1
What if you mean exclusivity (FDA data exclusivity) rather than a patent?
Patent expiry and regulatory exclusivity often get conflated. Even if a patent expires, exclusivity (depending on the product and regulatory pathway) can sometimes delay launch. If you tell me whether you want “patent expiry only” or “earliest possible market entry,” I can focus on that specific definition and point you to the matching dates in the patent record.
Sources